Company / Cash & Equivalents
Ryan Specialty Cash & Equivalents History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$158.3M
FY2025
5-year range
$158.3M / $992.7M
FY2021-FY2025
Trend
-70.7%
vs FY2024
Sector context
#206 of 256
Financials
What the data says
Ryan Specialty's cash & equivalents of $158M is lower than 80% of companies in the Financials sector (FY2025). Cash & Equivalents has declined for 3 consecutive years, from $993M in FY2022 to $158M in FY2025.
Based on SEC 10-K filings.
$158M in FY2025 with a 5-year CAGR of -29.3%.
Declined from $839M to $158M over the past 2 years.
Financials sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -45.8%
- 5-Year CAGR
- -29.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 20% in FinancialsTop 80% of 256This company $158.3M Sector average $2.8B
▼
-94.4% below sector average
Key checks
Key Insights
- Ryan Specialty's cash & equivalents has declined for 3 consecutive years.
- 5-year CAGR of -29.3%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 70.7% year-over-year.
- Ranks #206 out of 256 companies in the Financials sector.
Company context
Key Data Points
- Altman Z-Score 0.46 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $158.3M | -70.7% |
| FY2024 | $540.2M | -35.6% |
| FY2023 | $838.8M | -15.5% |
| FY2022 | $992.7M | +146.8% |
| FY2021 | $402.2M | -55.1% |
| FY2020 | $895.7M | +122.7% |
| FY2019 | $402.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026